...ocedure and streamlines the bisulfite method for D...hree step reaction that takes place between cytosi...d into uracil. The EZ DNA Methylation Kits innovat...everal precipitation steps and provides researcher...
Carbohydrate Analysis Standard, 6 vials from Bio-Rad
...s a dual capability system with the ability to pro...he specimen under test. While the XCAT series prov...mages, the micro focus source also allows the syst...images. The 50 mm x 50 mm digital detector provide...
General Side Effect Profile I (GEN SEP I) from Novascreen-a Caliper Life Sciences Company
Biology Products:(Date:12/1/2009)... California waste-to-energy firm claims first p...teration, smallest footprint, salable pure gas, by... (PRWEB) December 15, 2009 -- The...ative organic waste-to-energy process will take pl...nuary. , , ,This biowaste process known as VRAD&c...
(Date:11/30/2009)...ovember 30, 2009 An international team of applied... ETH Zrich have demonstrated compact, multibeam, a...le part of the light spectrum (infrared). By contr...well-defined wavelength. The innovative multibeam ...to remote chemical sensing pollution monitoring, o...
(Date:11/30/2009)... Nov. 30 The Michael J....day announced $1.5 million in total awards to six ...ase-modifying therapies for Parkinson,s disease. T... to Drug Discovery for Parkinson,s Disease progra... plc (NYSE: ELN ), a neuroscience-based biotechn...
(Date:11/30/2009)...RDAM, November 30 Biopharmaceutica...irst patients have been enrolled in its,multinatio... study is,designed to show reduction in transplant...an allogeneic stem cell transplantation with a mis...tients eligible for an allogeneic,stem cell transp...
Breaking Biology Technology:First Public Showing of Innovative Waste-to-Energy Process 2Scientists demonstrate multibeam, multi-functional lasers 2The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments 2The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments 3Kiadis Pharma Announces Enrollment of First Patients in a Multinational Registration Study for ATIR(TM) 2